Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2025-05-30 Proxy Solicitation & In…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
załącznik nr 7 - wzór pełnomocnictwa
Proxy Solicitation & Information Statement Classification · 98% confidence The document text is titled "FORMULARZ PEŁNOMOCNICTWA" (Proxy Form) and explicitly refers to the "Zwyczajne Walne Zgromadzenie Captor Therapeutics S.A." (Annual General Meeting of Captor Therapeutics S.A.) scheduled for June 26, 2025. This form is used by shareholders to appoint a representative (proxy) to vote on their behalf at a general meeting. This directly relates to the materials distributed to shareholders for the purpose of soliciting votes for a meeting, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). Although it is a form related to the AGM, it is the proxy document itself, not the AGM presentation (AGM-R) or the general notice/results (DVA).
2025-05-30 Polish
załącznik nr 6 - sprawozdanie Rady Nadzorczej Spółki za rok 2024
Board/Management Information Classification · 99% confidence The document is titled "Sprawozdanie Rady Nadzorczej Captor Therapeutics S.A. za rok 2024" which translates to "Report of the Supervisory Board of Captor Therapeutics S.A. for the year 2024". The content details the activities of the Supervisory Board, its composition, assessment of the company's situation, financial statements, corporate governance compliance, and remuneration policy for the year 2024. This structure strongly indicates a formal annual report or a specific statutory report required from the Supervisory Board, which often accompanies the main Annual Report (10-K equivalent in Polish context). Given the options, this document is a comprehensive report detailing the board's oversight and assessment for the full fiscal year (2024). While it is a specific type of report, it is not the primary 'Annual Report' (10-K) which usually contains the full financial statements and management discussion, but rather the Supervisory Board's statutory report on its activities and assessments. In many jurisdictions, this type of detailed oversight report is often filed alongside or as part of the broader annual reporting requirements. However, since it is a detailed report covering the entire year's activities and assessments, and not just a brief announcement, it aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed Audit/Oversight Report. Given the focus on the Supervisory Board's activities and assessment of management reports and financial statements for the year, it is most closely related to the comprehensive annual reporting cycle. If a specific 'Supervisory Board Report' code existed, it would be ideal. Lacking that, and considering it covers the full year's performance review and governance, it is closest to the scope of an Annual Report (10-K) or a detailed Audit Report (AR). Since it is explicitly the Supervisory Board's report assessing the management's report and financials for the year, and it is quite extensive, classifying it as an Audit Report (AR) which covers results of internal/regulatory stress tests and applied accounting principles (as the board assesses these) is a strong fit, especially if it's not the full 10-K. However, the content is primarily governance and oversight review for the year, which is a key component of the overall Annual Report package. Given the detailed nature covering the entire year (2024) and assessing financial statements and management reports, it functions as a core part of the annual disclosure. I will classify it as an Audit Report (AR) because it is the Supervisory Board's formal assessment/audit of the management's performance and financial reports for the year, which fits the description better than a general 10-K if the 10-K is reserved for the primary filing.
2025-05-30 Polish
załącznik nr 5 - raport niezależnego biegłego rewidenta z wykonania usługi dającej racjonalną pewność w zakresie oceny sprawozdania o wynagrodzeniach
Audit Report / Information Classification · 98% confidence The document is titled "Raport niezależnego biegłego rewidenta z wykonania usługi dającej racjonalną pewność w zakresie oceny sprawozdania o wynagrodzeniach" (Independent auditor's report on the performance of a reasonable assurance engagement on the remuneration report). It explicitly discusses the audit/review of a 'sprawozdanie o wynagrodzeniach' (remuneration report) based on Polish public offering laws (art. 90g). The content is the actual report from the auditor (Grant Thornton Polska) providing their conclusion on the completeness of the remuneration report. This fits the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles, distinguishing it from the full Annual Report (10-K) or a mere announcement of a report (RPA/RNS). The specific focus on remuneration reporting aligns closely with the scope covered by DEF 14A (Remuneration Information), but since this document is the *auditor's report* on that remuneration report, AR is the more precise classification for the assurance engagement document itself. FY 2024
2025-05-30 Polish
załącznik nr 4 - sprawozdanie o wynagrodzeniach za rok 2024
Remuneration Information Classification · 98% confidence The document is titled "Roczne Sprawozdanie o wynagrodzeniach Zarządu i Rady Nadzorczej za rok 2024" (Annual Report on the Remuneration of the Management Board and Supervisory Board for 2024). It details the composition of the Management Board and Supervisory Board, the components of their remuneration, and the total remuneration paid in 2024, referencing Polish law (Ustawa o ofercie publicznej). This content directly corresponds to the definition of a report detailing compensation for top executives and directors, which maps to the 'Remuneration Information' category. Although the content is about remuneration, the specific code provided for this type of disclosure is DEF 14A (Proxy Solicitation & Information Statement, often used for US filings covering executive compensation, but in this context, it is the closest fit for a detailed remuneration report that is often part of or related to proxy materials). Reviewing the definitions: - DEF 14A: Remuneration Information. Description: Report detailing compensation for top executives and directors. - This document is explicitly a detailed report on remuneration for the Management Board and Supervisory Board for the year 2024. Therefore, the classification is DEF 14A.
2025-05-30 Polish
załącznik nr 3 - treść uchwały Rady Nadzorczej pozytywnie opiniującej projekty uchwał
AGM Information Classification · 99% confidence The document is a formal resolution (Uchwała) from the Supervisory Board of Captor Therapeutics S.A. Specifically, Resolution No. 2 states that the Supervisory Board gives a favourable opinion on the draft resolutions for the Company's Ordinary General Meeting (OGM/Zwyczajne Walne Zgromadzenie). This action—the Supervisory Board providing an opinion on resolutions intended for a shareholder meeting—is a key component of the preparatory materials for an AGM. Since the content directly relates to the proceedings and required approvals leading up to the Annual General Meeting, the most appropriate classification is AGM Information (AGM-R). It is not a general regulatory filing (RNS) because it is highly specific to the AGM process.
2025-05-30 Polish
załącznik nr 2 - projekty uchwał ZWZ
AGM Information Classification · 100% confidence The document consists entirely of numbered resolutions ("UCHWAŁA nr X") passed by the "Zwyczajne Walne Zgromadzenie" (Ordinary General Meeting) of Captor Therapeutics S.A. on June 26, 2025. The content covers procedural matters (electing a chairman, adopting the agenda), approval of financial statements for 2024, covering losses, and granting discharge (absolutorium) to members of the Management Board and Supervisory Board for their duties in 2024. These are the core activities and documentation resulting from an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2025-05-30 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.